Upstream Bio Reports Q2 2026 Financial Results with Revenue Decline and Increased Net Loss

Upstream Bio, Inc. reported its financial results for the second quarter of 2026, revealing a collaboration revenue of $773,000 for the three months ended June 30, 2026, a decrease from $937,000 in the same period of 2025. For the six months ended June 30, 2026, the company generated $1.8 million in revenue, up from $1.5 million in the prior year. The increase in revenue is attributed to ongoing work related to the Phase 2 clinical trial and Phase 2 long-term extension study for severe asthma under the Maruho License Agreement. Despite this revenue growth, the company reported a net loss of $39.7 million for the second quarter, slightly improved from a loss of $39.9 million in the same quarter of the previous year. For the first half of 2026, the net loss was $80.3 million, compared to $67.2 million in the first half of 2025.

Operating expenses for Upstream Bio decreased to $43.1 million in the second quarter of 2026 from $45.3 million in the same quarter of 2025. This reduction was primarily driven by lower research and development costs, which fell to $36.1 million from $37.9 million year-over-year. The decrease in R&D expenses was largely due to a reduction in unallocated costs, although direct costs associated with the COPD indication increased as the company advanced its clinical trials. General and administrative expenses also saw a slight decline, totaling $7.1 million compared to $7.4 million in the prior year, reflecting a decrease in professional fees.

As of June 30, 2026, Upstream Bio's total assets amounted to $281.2 million, down from $353.8 million at the end of 2025. The decline in assets was primarily due to a reduction in cash and short-term investments, which decreased to $261.3 million from $341.5 million at the end of the previous fiscal year. The company’s accumulated deficit increased to $414.5 million, reflecting ongoing investment in research and development activities. The total number of shares outstanding rose to 54.8 million, up from 54.2 million at the end of 2025, as a result of stock-based compensation and shares issued under the company's at-the-market program.

Looking ahead, Upstream Bio anticipates continued significant operating losses as it progresses with its clinical trials for its lead product candidate, verekitug. The company plans to initiate Phase 3 trials for severe asthma and chronic rhinosinusitis with nasal polyps in early 2027. Upstream Bio has indicated that it will require additional financing to support its operations and growth strategy, as it does not expect to generate significant product revenue in the near term. The company believes its existing cash and investments will be sufficient to fund operations through 2027, but it will need to secure further capital to continue its development efforts and achieve its long-term objectives.